Keywords: Australia, Merck KGaA, Erbitux, KRAS gene testing, Bowel cancer, Colorectal

Genetic testing will decide who gets breakthrough cancer drug Erbitux in Australia

Article | 06 July 2010

Print This

Merck KGaA’s colorectal cancer drug is set to propel Australian health authorities headlong into a new era of personalized ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in